Indeed, as a result of its promising efficacy against MM, patients with relapsed or refractory MM were recently recruited for a phase I clinical trial of the EZH2 inhibitor, GSK126 (also known as GSK2816126)12. This evidence concerns the gene EZH2 and Miyoshi myopathy.